603087 Gan & Lee Pharmaceuticals.
- 48.65
- +0.20+0.41%
Gan & Lee Pharmaceuticals. News
Express News | Ganli Pharmaceutical: Director Mr. Yin Lei resigns
Ganli Pharmaceutical (603087.SH): Grant 7.04 million restricted shares to incentive recipients
Gelonghui, May 15, 丨 Ganli Pharmaceutical (603087.SH) announced that the company decided to grant 7.04 million restricted shares to 87 incentive recipients who met the grant conditions at a grant price of RMB 19.79 yuan/share on May 15, 2024.
Express News | Ganli Pharmaceutical: Senior management plans to increase holdings by 300,000 yuan to 500,000 yuan
Express News | Jin Tongling's financial fraud case involving Dahua was suspended for 6 months, and 15 A-share listed companies announced the cancellation of cooperation with them in the past 2 days
Ganli Pharmaceutical (603087): Performance is in line with expectations, continues to collect and win bids, and future profits can be expected
Incident: The company released its 2023 annual report & 2024 quarterly report. In 2023, it achieved revenue of 2.61 billion yuan (+52.3%), net profit to mother was 340 million yuan (+177.4%), net profit not attributable to mother
We Think That There Are Issues Underlying Gan & Lee Pharmaceuticals' (SHSE:603087) Earnings
Gan & Lee Pharmaceuticals.'s (SHSE:603087) robust earnings report didn't manage to move the market for its stock. We did some digging, and we found some concerning factors in the details. SHSE:603
Minsheng Securities released a research report on April 26 stating that it gave Ganli Pharmaceutical (603087.SH) a recommended rating. The main reasons for the rating include: 1) rapid growth in product sales, which turned a loss into a profit in 2023; 2)
Minsheng Securities released a research report on April 26 stating that it gave Ganli Pharmaceutical (603087.SH) a recommended rating. The main reasons for the rating include: 1) rapid growth in product sales, which turned a loss into a profit in 2023; 2) collection accelerated domestic replacement, and the company achieved rapid release of products; 3) renewals accelerated the pace of replacing second-generation insulin, further expanding the company's procurement base; 4) increasing investment in R&D and continuing to strengthen the sugar reduction product line; 5) speeding up the pace of going global and steadily advancing internationalization. (Mainichi Keizai Shimbun)
Ganli Pharmaceutical (603087): High-speed batch procurement of core products won the bid for the entire line
Guide to this report: The company's core products are being released at a high speed, and operational efficiency has improved markedly. The price increase for the entire line of collected products won the bid, which is expected to increase profits. Multiple potential catalysts, strong development momentum. Maintain an “Overweight” rating. Investment highlights: Performance is in line with expectations
Earnings Miss: Gan & Lee Pharmaceuticals. Missed EPS By 30% And Analysts Are Revising Their Forecasts
As you might know, Gan & Lee Pharmaceuticals. (SHSE:603087) last week released its latest quarterly, and things did not turn out so great for shareholders. Unfortunately, Gan & Lee Pharmaceutical
Ganli Pharmaceutical (603087.SH) reported 2023 results, with net profit of 340 million yuan, turning a year-on-year loss into a profit
Ganli Pharmaceutical (603087.SH) released its 2023 annual report, achieving revenue of 2,608 billion yuan, an increase of 52.31% over the previous year. Achieved net profit of 340 million yuan attributable to shareholders of listed companies, turning a year-on-year loss into a profit. Achieved net profit of 297 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, turning losses into profits over the previous year. It is proposed to distribute a cash dividend of 2 yuan (tax included) for every 10 shares to all shareholders.
Express News | Ganli Pharmaceutical: Net profit increased 95.04% year-on-year in the first quarter of 2024
Guojin Securities: Continued increase in domestic insulin share is expected to drive continued growth in performance
Since May 2022, national special insulin collection has been launched in various provinces and cities. While the price of insulin products has declined, the domestic substitution process has greatly accelerated.
Huatai Securities: National insulin collection contract renewal and bid opening, leading domestic companies are expected to maintain gross margin above 80%
The Zhitong Finance App learned that Huatai Securities released a research report stating that on April 23, the national insulin collection contract was renewed and opened. The current collection volume was about 60% of the country's total demand, and the overall price was reduced by about 3.8%, and the bid period was until the end of '27. The rules for this collection were gentle, and it was stipulated that 92% of the products were selected. Among them, Ganli Pharmaceutical, Hefei Tianmai, and Yifan Biotech rose across the board, while Tonghua Dongbao dropped moderately and all were selected in Class A. The current collection renewal price favors leading domestic companies. The gross margin of leading domestic insulin companies is expected to remain above 80%; at the same time as the prices of some domestic companies are rising
Express News | The net inflow of the 8-share mega-order exceeded 100 million yuan
Express News | Ganli Pharmaceutical: The company participated in the national centralized drug procurement (insulin special continuation) to win the bid
The bid for insulin collection was opened, and Ganli Pharmaceutical won the bid higher than the previous national procurement
Gan Li Pharmaceutical participated in the bidding for the successive procurement of 6 products. All 6 bid products won the bid, and the prices all increased compared to the previous domestic procurement.
Innovative drug concepts fluctuated in the afternoon, and Ganli Pharmaceutical rose and stopped
The innovative drug concept fluctuated and rebounded in the afternoon. Gan Li Pharmaceutical rose and stopped, while Kain Technology, Osecon, Yifan Pharmaceutical, Gibel, and Rongchang Biotech followed suit.
Express News | Tonghua Dongbao Insulin won the bid for successive insulin purchases at the lowest price
Ganli Pharmaceutical continues to purchase 6 competitive products and increases prices across the board
Gelonghui, April 23 | According to the Science and Technology Innovation Board Daily, we learned at the special insulin procurement site on the 23rd that Gan Li Pharmaceutical participated in the bidding for 6 products in this succession. All 6 of the products bid won the bid, and the price increased compared to the previous domestic procurement. The six products participating in the bid were: insulin glargine injection, insulin injection, menthong insulin injection, argentin-zinc recombinant laipro insulin mixed injection (25R), insulin 30 injection, and spermatin human insulin mixed injection (30R). Quotation points corresponding to the 3ml: 300 units (refills) specifications for 6 products
Express News | At the insulin collection renewal site, Ganli Pharmaceutical announced the offer
Analysis
Price Target
No Data
